Although further research and clinical trials are needed to fully understand the potential of JAC1 as an inhibitor of YY1, JAC1 could serve as a potential antitumor agent for YY1-overexpressed malignant tumors since YY1 is highly expressed in many cancers and regulates genes related to the cell cycle, cell death, and tumor metabolism. Here, HSCB is linked to neoplasm.